2007 1. Adamek, A., et al., High dose aspirin and left ventricular ...

Engl J Med, 2007. 356(23): p. 2372-80.
67. Thum, T. and S.D. Anker, Nutritional iron deficiency in patients with chronic
illnesses. Lancet, 2007. 370(9603): p. 1906.
68. Thum, T. and J. Bauersachs, Microarray-based gene expression profiling to
elucidate cellular responses to nitric oxide--a review from an analytical and
biomedical point of view. J Chromatogr B Analyt Technol Biomed Life Sci, 2007.
851(1-2): p. 3-11.
69. Thum, T., et al., Growth hormone treatment improves markers of systemic nitric
oxide bioavailability via insulin-like growth factor-I. J Clin Endocrinol Metab, 2007.
92(11): p. 4172-9.
70. Thum, T., et al., Endothelial nitric oxide synthase uncoupling impairs endothelial
progenitor cell mobilization and function in diabetes. Diabetes, 2007. 56(3): p.
666-74.
71. Thum, T., et al., Differential effects of organic nitrates on endothelial progenitor
cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol, 2007.
27(4): p. 748-54.
72. Thum, T., et al., MicroRNAs in the human heart: a clue to fetal gene
reprogramming in heart failure. Circulation, 2007. 116(3): p. 258-67.
73. Thum, T., et al., Age-dependent impairment of endothelial progenitor cells is
corrected by growth-hormone-mediated increase of insulin-like growth-factor-1.
Circ Res, 2007. 100(3): p. 434-43.
74. To, T.T., et al., Pituitary-interrenal interaction in zebrafish interrenal organ
development. Mol Endocrinol, 2007. 21(2): p. 472-85.
75. Tordoir, J., et al., EBPG on Vascular Access. Nephrol Dial Transplant, 2007. 22
Suppl 2: p. ii88-117.
76. Tripepi, G., et al., Measures of effect: relative risks, odds ratios, risk difference,
and 'number needed to treat'. Kidney Int, 2007. 72(7): p. 789-91.
77. Tsikas, D., et al., Accurate quantification of dimethylamine (DMA) in human urine
by gas chromatography-mass spectrometry as pentafluorobenzamide derivative:
evaluation of the relationship between DMA and its precursor asymmetric
dimethylarginine (ADMA) in health and disease. J Chromatogr B Analyt Technol
Biomed Life Sci, 2007. 851(1-2): p. 229-39.
78. von Eynatten, M., et al., Retinol-binding protein 4 is associated with components
of the metabolic syndrome, but not with insulin resistance, in men with type 2
diabetes or coronary artery disease. Diabetologia, 2007. 50(9): p. 1930-7.
79. Wagner, J.A., et al., Natriuretic peptides and myocardial oxygen supply-todemand
ratio in patients with aortic stenosis. Eur J Clin Invest, 2007. 37(6): p.
463-71.
80. Wanner, C., Fabry disease model: a rational approach to the management of
Fabry disease. Clin Ther, 2007. 29 Suppl A: p. S2-5.
81. Wanner, C., On statin treatment to prevent sepsis in dialysis patients. Am J
Kidney Dis, 2007. 50(5): p. 700-2.
82. Wanner, C., Fabry disease: clinical outcomes of agalsidase enzyme replacement
therapies. Int J Clin Pract, 2007. 61(7): p. 1234-5; author reply 1235.
83. Wanner, C. and F. Breunig, Fabry nephropathy and the case for adjunctive renal
therapy. J Am Soc Nephrol, 2007. 18(9): p. 2426-8.